-transparent.png){kind=logo}
Furosemide (40 mg) was administered to 18 healthy adult males as an intravenous dose, an oral solution, and in tablet form. The pharmacokinetics of intravenous furosemide were studied, determining a total body clearance rate of 117.6 +/- 41.3 ml/min and a harmonic mean half-life of 78 min. The mean absolute bioavailability determined by ratio of areas under the plasma-time curves was 64 and 71% for the solution and tablet, respectively. The mean absolute bioavailability determined by the ratio of urinary cumulative excretion data was 61 and 66% for the solution and tablet, respectively. The absolute bioavailability of furosemide determined with plasma and urine data were not significantly different. Thus, urine data alone may be used to establish bioavailability of furosemide. Inspection of plasma-time curves revealed secondary maxima in several subjects, suggesting enterohepatic cycling.
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
August 2008,
Journal of clinical pharmacology,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
July 2006,
Journal of clinical pharmacology,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
September 1998,
Biopharmaceutics & drug disposition,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
January 1996,
Drug metabolism and disposition: the biological fate of chemicals,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
February 2019,
Clinical pharmacology in drug development,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
January 1993,
Drug metabolism and disposition: the biological fate of chemicals,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
May 2018,
BMC pharmacology & toxicology,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
January 2013,
Clinical pharmacology in drug development,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
October 1990,
British journal of clinical pharmacology,
E S Waller, and
S F Hamilton, and
J W Massarella, and
M A Sharanevych, and
R V Smith, and
G J Yakatan, and
J T Doluisio
December 1997,
Biopharmaceutics & drug disposition,
